Tiger Brokers

BRIEF-Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
Mar 27
BRIEF-Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co LLY.N:

  • LILLY'S EBGLYSS (LEBRIKIZUMAB-LBKZ) DELIVERED UP TO FOUR YEARS OF DURABLE DISEASE CONTROL FOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • ELI LILLY - EBGLYSS DELIVERS FOUR YEARS OF DURABLE DISEASE CONTROL FOR ATOPIC DERMATITIS

  • ELI LILLY - EBGLYSS SHOWS CONSISTENT SAFETY PROFILE WITH NO NEW SAFETY SIGNALS IN FIRST YEAR

Source text: ID:nPn9Z3gRa

Further company coverage: LLY.N

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10